Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review

被引：9

作者：

Serban, Dragos ^{[1
,2
]}

Costea, Daniel Ovidiu ^{[3
,4
]}

Zgura, Anca ^{[5
,6
]}

Tudosie, Mihail Silviu ^{[7
,8
]}

Dascalu, Ana Maria ^{[9
,10
]}

Gangura, Gabriel Andrei ^{[1
,11
]}

Smarandache, Catalin Gabriel ^{[1
,2
]}

Sabau, Alexandru Dan ^{[12
,13
]}

Tudor, Corneliu ^{[2
]}

Faur, Mihai ^{[12
,13
]}

Costea, Andreea Cristina ^{[14
]}

Stana, Daniela ^{[10
]}

Balasescu, Simona Andreea ^{[2
]}

Tribus, Laura Carina ^{[15
,16
]}

Tanasescu, Ciprian ^{[12
,13
]}

机构：

[1] Carol DavilaUniv Med & Pharm, Dept Gen Surg, Fac Med, Bucharest, Romania

[2] Emergency Univ Hosp, Dept Surg Emergency 4, Bucharest, Romania

[3] Ovidius Univ, Fac Med, Dept Clin Surg Disciplines 1, Constanta, Romania

[4] Emergency Cty Hosp, Surg Dept 1, Constanta, Romania

[5] Carol DavilaUniv Med & Pharm, Fac Med, Dept Oncol Radiol & Hematol, Bucharest, Romania

[6] Inst Oncol Prof Dr Alexandru Trestioreanu, Dept Oncol Radiotherapy, Bucharest, Romania

[7] Carol Davila Univ Med & Pharm, Fac Med, Dept Orthopedia & Intens Care, Bucharest, Romania

[8] Clin Emergency Hosp, ICU Toxicol 2, Bucharest, Romania

[9] Carol Davila Univ Med & Pharm, Fac Med, Dept ENT Ophthalmol, Bucharest, Romania

[10] Emergency Univ Hosp, Ophthalmol Dept, Bucharest, Romania

[11] Emergency Univ Hosp, Dept Surg 2, Bucharest, Romania

[12] Lucian Blaga Univ, Fac Med, Surg Clin Dept, Sibiu, Romania

[13] Sibiu Cty Emergency Clin Hosp, Dept Surg, Sibiu, Romania

[14] Diaverum Clin, Nephrol & Dialysis Dept, Constanta, Romania

[15] Carol Davila Univ Med & Pharm, Dept Internal Med Gastroenterol, Fac Med, Bucharest, Romania

[16] Emergency Univ Hosp Bucharest, Gastroenterol Dept, Bucharest, Romania

来源：

IN VIVO | 2022年 / 36卷 / 01期

关键词：

Breast cancer; endocrine therapy; aromatase inhibitors; ocular side-effects; dry eye; anastrozole; review; DRY-EYE SYNDROME; POSTMENOPAUSAL WOMEN; ADJUVANT TREATMENT; TAMOXIFEN THERAPY; RANDOMIZED-TRIAL; SURFACE DISEASE; ANASTROZOLE; ESTROGEN; LETROZOLE; EXEMESTANE;

D O I：

10.21873/invivo.12674

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

in patients with breast cancer. Materials and Methods: A comprehensive search was performed on PubMed, Web of Science and Google scholar. Results: After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema. Conclusion: Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.

引用

页码：40 / 48

页数：9

共 50 条

[1] Endocrine therapy after aromatase inhibitor therapy in breast cancer
Verma, Mohit K.
Miki, Yasuhiro
Sasano, Hironobu
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2011, 6 (03) : 309 - 312
[2] Side effects of endocrine therapy for breast cancer
Diesing, D.
Friedrich, M.
von Otte, S.
GYNAKOLOGISCHE ENDOKRINOLOGIE, 2005, 3 (02): : 91 - 96
[3] Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients
Sini, Valentina
Botticelli, Andrea
Lunardi, Gianluigi
Gori, Stefania
Marchetti, Paolo
PHARMACOGENOMICS, 2017, 18 (08) : 821 - 830
[4] Side effects of endocrine therapy in patients with breast cancer
Douglas, SL
Dillon, P
Anderson, A
Cameron, DA
Leonard, T
Leonard, RCF
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S313 - S314
[5] Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects
Berstein, L
Maximov, S
Gershfeld, E
Meshkova, I
Gamajunova, V
Tsyrlina, E
Larionov, A
Kovalevskij, A
Vasilyev, D
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2002, 105 (02): : 161 - 165
[6] Is an aromatase inhibitor more effective than tamoxifen in neoadjuvant endocrine therapy for breast cancer?
Roukos, DH
Fatouros, M
Paraskevaidis, E
Kappas, AM
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (02): : 82 - 83
[7] Is an aromatase inhibitor more effective than tamoxifen in neoadjuvant endocrine therapy for breast cancer?
Dimitrios H Roukos
Michael Fatouros
Evangelos Paraskevaidis
Angelos M Kappas
Nature Clinical Practice Oncology, 2006, 3 : 82 - 83
[8] Managing side effects in adjuvant endocrine therapy for breast cancer
Condorelli, Rosaria
Vaz-Luis, Ines
EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (11) : 1101 - 1112
[9] Safety of aromatase inhibitor therapy in breast cancer
Lintermans, Anneleen
Neven, Patrick
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (08) : 1201 - 1211
[10] Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
Huifang, Li
Jie, Gao
Yi, Feng
FRONTIERS IN ONCOLOGY, 2022, 12

← 1 2 3 4 5 →